Newsletter Tool

Today’s Big News

Jul 17, 2025

Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning

Novartis' B-cell-depleting antibody fails to show promise in phase 2 dermatology study

BioNTech’s chief strategy officer Richardson heads for the exit

Otsuka inks $613M deal for Swedish biotech's autoimmune antibodies

I-Mab buys Bridge Health for $3M-plus to strengthen pivot to CLDN18.2 bispecific

Okyo sets sights on first approval in neuropathic eye pain after phase 2 win

FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns

For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 3

Featured

Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning

By Gabrielle Masson

Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually.

Novartis' B-cell-depleting antibody fails to show promise in phase 2 dermatology study

By James Waldron

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study.

BioNTech’s chief strategy officer Richardson heads for the exit

By Nick Paul Taylor

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to "pursue new professional opportunities."

How do you get pharmaceutical treatments where they’re needed most?

Sponsored by Evernorth Specialty Services

Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, therapy fulfillment and generalized patient care.

Otsuka inks $613M deal for Swedish biotech's autoimmune antibodies

By Gabrielle Masson

Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune and inflammatory diseases.

I-Mab buys Bridge Health for $3M-plus to strengthen pivot to CLDN18.2 bispecific

By James Waldron

I-Mab has solidified its pivot to givastomig by buying out the owner of an antibody used in the therapy.

Okyo sets sights on first approval in neuropathic eye pain after phase 2 win

By Darren Incorvaia

Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition. Okyo Pharma’s urcosimod reduced pain levels by an average of 5.5 on a 10-point scale, hitting the primary endpoint of a phase 2 trial and teeing up a meeting with the FDA about next steps.

FDA hands down citations to 3 drugmakers after inspections found contamination, testing concerns

By Zoey Becker

The FDA listed observations at plants run by Sun Pharma, Daewoo Pharmaceutical and Glenmark, citing concerns ranging from mold to quality control issues.

For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 3

By Angus Liu

The FDA is asking an expert panel to weigh in on “discordant results” from three randomized trials related to Lundbeck and Otsuka's application for a Rexulti combination regimen in PTSD.

After recall, Pfizer warns of 'near-term stock out' of penicillin product used to treat syphilis in pregnant women

By Fraiser Kansteiner

Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ubiquitous antibiotic.

Johnson & Johnson boosts financial projections with growing cardiac device sales

By Conor Hale

“We are not rolling over,” J&J MedTech’s worldwide chairman, Tim Schmid, said on the company’s quarterly earnings call with investors.

Fierce podcasts

Don’t miss an episode

Whole health, whole new med school: Alice Walton’s vision comes to life in Arkansas

In this episode of "Podnosis," we explore how Walmart heir Alice Walton’s new medical school in Arkansas is rethinking medical education with a whole health approach that values empathy, the arts and business alongside clinical training.

Biopharma layoffs aren't letting up

What employers want from specialty care

Resources

Whitepaper

Industry-backed, data-driven approaches to enhancing container closure integrity

This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance.

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.